The Latest New Treatment Innovations

You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!

Key Questions
  • The International Headache Society recently titled its conference “Dawn of New Headache Treatments.” What makes this such an important time for migraine?
  • How do the new CGRP drugs — Aimovig, Ajovy, Emgality, and Vyepti — work?
  • What are some of the side effects of these medications?
  • How are people responding to the new CGRP drugs, now that a few hundred thousand have tried them?
  • Is there anyone who should not use the CGRP medications?
  • What is the mechanism behind some of the neuromodulation devices, such as the Nerivio, CEFALY, gammaCore, and sTMS devices?
  • How safe and how effective are neuromodulation devices?
  • What can you tell us about the new class of acute medication coming out, the ditans?
  • Will taking a ditan feel different than what taking a triptan feels like for some people with migraine?
  • What can you tell us about yet another class of medication coming out, the gepants?
  • How do these new classes of drugs, the gepants and ditans, differ from triptans?
Interview Notes
Peter Goadsby

Peter Goadsby, MD

Professor of Neurology and Neurologist
King's College London, UK

Dr. Peter J. Goadsby is one of the world’s leading headache neurologists and researchers, and a professor at King’s College London and the University of California, Los Angeles (UCLA). Dr. Goadsby is on the board of directors for the American Headache Society, as well as the American Migraine Foundation, in addition to serving on the American Registry Migraine Research (ARMR) scientific advisory board and executive committee. Dr. Goadsby is also a trustee for The Migraine Trust. He was one of the first to explore CGRP (calcitonin gene-related peptide), the protein known for its involvement in migraine. This discovery has been instrumental in creating the new class of medications CGRP receptor antagonists, including Aimovig, Ajovy, Emgality, and Vyepti.

Watch at your own pace & get additional expert interview footage when you purchase the 2023 Migraine World Summit. Includes:

  • All expert interviews with seperate audio (MP3) files & transcripts
  • 30 extended, uncut interview editions with 6.5 hours of bonus expert footage
  • Lifetime access with no annual fee
Access Pass options

Related Talks for: Day 7 (2020) Treatments

Are Migraine Surgeries Worth It?

William B. Young, MD

Real-World Use of CGRP Medications

Brian Grosberg, MD

Multi-Disciplined Approach to Migraine Management

Tine Poole, MD

New Treatments

Timothy R. Smith, MD, RPH

The Association of Migraine Disorders (AMD) is devoted to expanding the understanding of migraine disease and its true scope. Migraine is a full body condition with a broad spectrum of symptoms, AMD is focused on including many medical specialties in the management of this disease.

Learn more

View more/less

Theranica develops advanced yet affordable electroceuticals, addressing a few prevalent neurological pain diseases. The company’s first FDA-authorized product, Nerivio™, is available in the US. Nerivio is an innovative, non-invasive, smartphone-operated, prescribed wearable for the acute treatment of migraine. 12% of the world’s population suffer from migraine, of which 80% are women. Being completely drug-free, Nerivio™ is a safe, addiction-free alternative in the multi-billion-dollar market of medications for migraine.

Learn more

View more/less

Summaries now available for every interview with expert quotes, treatments mentioned, action items. Start making positive changes today with these guides. Only available with 2020 VIP Access Pass.

View more/less

Leave a comment

Back to top